bioRxiv Science⌕ Search

Biology subjects

QI, C.

Publications and source records attributed to QI, C..

2 recordsLinked to original sources

Discovery and Engineering of a New BvCas12a Nuclease for Mammalian Genome Editing and Nucleic Acid Detection

Cas12a is an RNA-guided endonuclease that has emerged as a powerful gene-editing tool. We have identified a novel Cas protein, BvCas12a, from Butyricimonas virosa with a 5-TYTN protospacer adjacent motif (PAM). BvCas12a exhibits double-stranded DNA cleavage activity in vitro and genome editing activity in eukaryotic cells. Though the editing efficiency of BvCas12a is marginally lower than that of AsCas12a, the editing specificity of BvCas12a in eukaryotic cells is comparable or superior to that of AsCas12a. Moreover, BvCas12a exhibits substantial collateral activity and can detect HPV DNA effectively and accurately in conjunction with isothermal amplification, highlighting its potential in nucleic acid diagnostics. Furthermore, we have engineered BvCas12a to create two variants, BvCas12a-R (N549R, T606P) and BvCas12a-RVR (N549R, K555V, C559R, T606P). These variants recognize expanded 5-YYN and 5-YN PAM in vitro, respectively. Additionally, they exhibit higher editing activity than wild-type BvCas12a and recognize 5-YYN PAM in vivo at all sites detected. In conclusion, we have identified a novel BvCas12a protein with high specificity and engineered two variants with broader PAM compatibility and improved genome editing efficiency. These findings offer a potent gene editing tool for application in scientific research, gene therapy, and nucleic acid diagnostics.

genomics↗

CAMOIP: A Web Server for Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer

Immune checkpoint inhibitors (ICIs) have completely changed the therapeutic approach for tumor patients. Immunotherapy has also produced much needed data about mutation, expression, and prognosis, providing an unprecedented opportunity for discovering candidate drug targets and screening for immunotherapy-relevant biomarkers. Although existing web tools enable biologists to analyze the expression, mutation, and prognosis data on tumors, they are currently not able to carry out data mining and mechanism analyses related to immune checkpoint therapy. Thus, we developed our own web-based tool called Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer (CAMOIP), in which we can screen prognostic markers and analyze the mechanisms involved with markers and immunotherapy (more than 4000 patients). The analyses include survival analysis, expression analysis, drug sensitivity analysis, mutational landscape, immune checkpoint analysis, immune related signature analysis, immune cell analysis, immune gene analysis, immunogenicity analysis and gene sets enrichment analysis (GSEA). This comprehensive analysis of biomarkers for immunotherapy can be carried out by a click of CAMOIP, and the software should greatly encourage the further development of immunotherapy. CAMOIP fills the gap between the big data of cancer genomics based on immunotherapy and providing comprehensive information to users, helping to release the value of current ICI-treated data resources. CAMOIP can be found in https://www.camoip.net.

genomics↗